LEADER 04247nam 2200541 450 001 9910463370603321 005 20200520144314.0 010 $a3-11-047855-2 024 7 $a10.1515/9783110480436 035 $a(CKB)3340000000003259 035 $a(MiAaPQ)EBC5043144 035 $a(DE-B1597)466579 035 $a(OCoLC)1004872200 035 $a(DE-B1597)9783110480436 035 $a(Au-PeEL)EBL5043144 035 $a(CaPaEBR)ebr11438523 035 $a(CaONFJC)MIL1035418 035 $a(OCoLC)1004194904 035 $a(EXLCZ)993340000000003259 100 $a20171014h20172017 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aIron-sulfur clusters in chemistry and biology /$fedited by Tracey Rouault 205 $a2. Aufl. 210 1$aBerlin, [Germany] ;$aBoston, [Massachusetts] :$cDe Gruyter,$d2017. 210 4$d©2017 215 $a1 online resource (466 pages) $cillustrations 225 0 $aIron-Sulfur Clusters in Chemistry and Biology ;$vVolume 1 311 $a3-11-048043-3 311 $a3-11-047850-1 320 $aIncludes bibliographical references and index. 327 $tFrontmatter -- $tPreface -- $tTracey A. Rouault biography -- $tContents -- $tList of contributing authors -- $t1. Iron-sulfur proteins: a historical perspective / $rBonomi, Francesco / Rouault, Tracey A. -- $t2. Chemistry of iron-sulfur clusters / $rIchiye, Toshiko -- $t3. From the quantum chemistry of iron-sulfur clusters to redox energetics and reaction pathways in metalloenzymes / $rNoodleman, Louis -- $t4. Bioinorganic spectroscopy of iron sulfur proteins- an overview / $rGuo, Yisong / Li, Jikun -- $t5. Quantitative interpretation of EPR spectroscopy with applications for iron-sulfur proteins / $rPetasis, Doros T. / Hendrich, Michael P. -- $t6. The utility of Mössbauer spectroscopy in eukaryotic cell biology and animal physiology / $rChakrabarti, Mrinmoy / Lindahl, Paul A. -- $t7. The interstitial carbide of the nitrogenase M-cluster: insertion pathway and possible function / $rSickerman, Nathaniel S. / Ribbe, Markus / Hu, Yilin -- $t8. The iron-molybdenum cofactor of nitrogenase / $rSpatzal, Thomas / Andrade, Susana L. A. / Einsle, Oliver -- $t9. Biotin synthase: a role for iron-sulfur clusters in the radical-mediated generation of carbon-sulfur bonds / $rJarrett, Joseph T. -- $t10. Molybdenum-containing iron-sulfur enzymes / $rHille, Russ -- $t11. The role of iron-sulfur clusters in the biosynthesis of the lipoyl cofactor / $rLanz, Nicholas D. / Booker, Squire J. -- $t12. Iron-sulfur clusters and molecular oxygen: function, adaptation, degradation, and repair / $rNicolet, Yvain / Fontecilla-Camps, Juan C. -- $t13. Reactivity of iron-sulfur clusters with nitric oxide / $rDodd, Erin L. / Crack, Jason C. / Thomson, Andrew J. / Le Brun, Nick E. -- $tIndex 330 $aThis volume on iron-sulfur proteins includes chapters that describe the initial discovery of iron-sulfur proteins in the 1960s to elucidation of the roles of iron sulfur clusters as prosthetic groups of enzymes, such as the citric acid cycle enzyme, aconitase, and numerous other proteins, ranging from nitrogenase to DNA repair proteins. The capacity of iron sulfur clusters to accept and delocalize single electrons is explained by basic chemical principles, which illustrate why iron sulfur proteins are uniquely suitable for electron transport and other activities. Techniques used for detection and stabilization of iron-sulfur clusters, including EPR and Mossbauer spectroscopies, are discussed because they are important for characterizing unrecognized and elusive iron sulfur proteins. Recent insights into how nitrogenase works have arisen from multiple advances, described here, including studies of high-resolution crystal structures. 606 $aTrace elements in nutrition 608 $aElectronic books. 615 0$aTrace elements in nutrition. 676 $a612.3/924 702 $aRouault$b Tracey A. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910463370603321 996 $aIron-Sulfur Clusters in Chemistry and Biology$91504563 997 $aUNINA LEADER 05142nam 2200409 450 001 9910765705803321 005 20230323191246.0 010 $a3-03897-281-9 035 $a(CKB)5400000000000165 035 $a(NjHacI)995400000000000165 035 $a(EXLCZ)995400000000000165 100 $a20230323d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAML in the molecular age $efrom biology to clinical management /$fedited by Celalettin Ustun, Lucy A. Godley 210 1$aBasel, Switzerland :$cMDPI,$d[2018] 210 4$d©2018 215 $a1 online resource (196 pages) 225 0 $aJournal of clinical medicine 320 $aIncludes bibliographical references. 327 $aAbout the Special Issue Editors . vii -- Preface to "AML in the Molecular Age: From Biology to Clinical Management" ix -- Sophia Yohe Molecular Genetic Markers in Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 460-478, doi: 10.3390/jcm4030460 . 1 -- Gustavo M. Cervantes and Zuzan Cayci Intracranial CNS Manifestations of Myeloid Sarcoma in Patients with Acute Myeloid Leukemia: Review of the Literature and Three Case Reports from the Author's InstitutionReprinted from: J. Clin. Med. 2015, 4, 1102-1112, doi: 10.3390/jcm4051102 . 16 -- Elzbieta Gocek and George P. Studzinski The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy Reprinted from: J. Clin. Med. 2015, 4, 504-534, doi: 10.3390/jcm4040504 . 25 -- Caroline Benedicte Nitter Engen, Line Wergeland, Jørn Skavland and Bjørn Tore Gjertsen Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions Reprinted from: J. Clin. Med. 2014, 3, 1466-1489, doi: 10.3390/jcm3041466 . 50 -- Marjan Cruijsen, Michael L ¨ubbert, Pierre Wijermans and Gerwin Huls Clinical Results of Hypomethylating Agents in AML Treatment Reprinted from: J. Clin. Med. 2015, 4, 1-17, doi: 10.3390/jcm4010001 . 69 -- Prithviraj Bose and Steven Grant Rational Combinations of Targeted Agents in AML Reprinted from: J. Clin. Med. 2015, 4, 634-664, doi: 10.3390/jcm4040634 . 83 -- Guldane Cengiz Seval and Muhit Ozcan Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients Reprinted from: J. Clin. Med. 2015, 4, 441-459, doi: 10.3390/jcm4030441 . 107 -- Jasmijn D. E. de Rooij, C. Michel Zwaan and Marry van den Heuvel-Eibrink Pediatric AML: From Biology to Clinical Management Reprinted from: J. Clin. Med. 2015, 4, 127-149, doi: 10.3390/jcm4010127 . 122 -- Gabriela Soriano Hobbs and Miguel-Angel Perales Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients Reprinted from: J. Clin. Med. 2015, 4, 488-503, doi: 10.3390/jcm4030488 . 140 -- Nelli Bejanyan, Housam Haddad and Claudio Brunstein Alternative Donor Transplantation for Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 1240-1268, doi: 10.3390/jcm4061240 . 152 -- Nestor R. Ramos, Clifton C. Mo, Judith E. Karp and Christopher S. Hourigan Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 665-695, doi: 10.3390/jcm4040665 . 174. 330 $aIn this Special Issue, we aim to discuss important scientific and clinical ongoing activities in AML. Scientific subjects will include articles concerning the molecular abnormalities, epigenetic mechanisms of disease/therapy as well as the role of the immune system in AML. Very interesting and uncommon subjects will include discussions of extramedullary disease and evaluations of the central nervous system by various imaging techniques. Experts will describe the role of hypomethylating agents in the management of AML and currently emerging and promising investigational therapies. Specifics of treament of pediatric and younger patients with AML. Clinical success relies greatly on supportive therapy, and we will discuss supportive therapy, including infection prophylaxis. Allogeneic hematopoietic stem cell transplantation remains the most effective measure for curing aggressive AML, and a variety of topics will be considered: donor selection, age of recipient, which has been increasing seemingly without limit; therefore, recipient/donor assessments are more important than ever in the aging population. Alternative donor use (e.g., cord blood and haploidentical individuals) has been increasing dramatically; when and who should be considered, what is being investigated? With signi?cant changes occurring with respect to both donors and recipients, the pros and cons of using of anti-thymocyte globulin use in conditioning regimens will be also described. 517 $aAML in the Molecular Age 606 $aAcute myeloid leukemia 615 0$aAcute myeloid leukemia. 676 $a616.99/419 702 $aUstun$b Celalettin 702 $aGodley$b Lucy A. 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910765705803321 996 $aAML in the molecular age$93395475 997 $aUNINA